Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Astex, Foundation Medicine, Inc., Daiichi Sankyo Inc, Genentech, and Jazz Pharmaceuticals, Inc.
ASH: New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice
Friday, November 30, 2018
Dinner and registration: 6:00 PM – 7:00 PM
Manchester Grand Hyatt San Diego
Dinner Room: Grand Hall D, Lobby Level
Symposia Room: Grand Hall D, Lobby Level
1 Market Place
San Diego, CA 92101
Keeping up with the unprecedented development of new therapies for patients with acute myeloid leukemia (AML) has become particularly challenging for busy clinicians. The past 2 years have seen nearly a dozen new agents approved or in review by regulatory authorities, including inhibitors of FLT3, isocitrate dehydrogenase (IDH), and BCL-2, as well as hypomethylating agents, anti-CD33 agents, and novel cytotoxic formulations. Moreover, use of these new therapies is increasingly being tied to molecular markers. These developments have changed the paradigm of care for patients with AML.
To help you better navigate the changing therapeutic landscape, we are pleased to present New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice, a cutting-edge program designed to help you apply with confidence the latest therapeutic developments for your patients with AML.
If you are able to take part in this exciting event, we hope to augment your foundation of knowledge and clinical competence in several areas, including:
- Recent data on next-generation FLT3 inhibitors in newly diagnosed patients with relapsed/refractory AML
- Expanding applications for IDH inhibition, including both IDH1 and IDH2
- New approaches for patients with AML who are not candidates for intensive therapy
- Managing therapy-related adverse events
This educational activity is directed toward medical oncologists/hematologists, nurse practitioners, nurses, and fellows who treat and manage patients with AML. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of AML are also invited to participate.
Upon completion of this activity, participants should be able to:
- Identify prognostic factors for risk stratification in patients with AML, methods to apply testing strategies and their findings, and monitoring strategies for patients managed for these tumors
- Detail results from recent clinical trials that have evaluated emerging treatment strategies for patients with AML
- Apply emerging data sets in the context of evolving treatment paradigms in the management of AML
- Apply evidence-based strategies for proactive management of treatment-related toxicities that occur in the real-world management of patients with AML
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Astex, Foundation Medicine, Inc., Daiichi Sankyo Inc, Genentech, and Jazz Pharmaceuticals, Inc.
Naval G. Daver, MD
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.